• KTEC History
• KTEC Officers
• KTEC Board of Directors
• Location
  • Map of Topeka
  • Downtown Detail Map
  • Available Parking
• Partners
• Frequently Asked Questions
• KTEC Publications
• KTEC Success Stories

KTEC Success Stories

BeyondNow acquisition nets large return for Kansas

The acquisition of BeyondNow Technologies by Cerner Corporation, announced last month, has produced 120 percent return on investment for the state of Kansas via the Kansas Technology Enterprise Corporation (KTEC).

In 1997, KTEC invested $100,000 in BeyondNow to assist the company in developing its software for the home health care industry in a Windows format. Windows versions of two of BeyondNow's primary products, HomeWorks and RoadNotes, were developed as a result of this investment.

In addition to providing a return on investment for KTEC and Kansas, BeyondNow also created more than 60 quality jobs in Kansas since its inception.

"This really is a win-win-win situation for BeyondNow, KTEC and the state of Kansas," said Tracy Taylor, KTEC president and CEO. "BeyondNow will be able to further develop its products, KTEC can reinvest its return into other Kansas companies, and the state has more than 60 well-paid taxpayers."

More information: http://www.beyondnow.com

KTEC invests in Inverseon

KTEC has made a seed round investment in Overland Park, Kan.-based Inverseon Inc. from its Technology Commercialization Seed Fund (TCSF). Inverseon is a newly created biopharmaceutical company that focuses on the development of an orally available small molecule for the treatment of asthma. The company's technology is built around the development of inverse agonists, substances that may help asthma patients who have become resistant to other treatments. KTEC's TCSF program is designed to stimulate the commercialization of new products, processes or technologies with the goal of increasing sales for the company and creating jobs for Kansans.

Cydex lands $17 million in venture capital

Cydex Pharmaceuticals, a KTEC investment recipient, recently announced that it had received $17 million in funding from a syndicate of investors including Sanders Morris Harris, a Houston-based firm, and the venture capital arms of GlaxoSmithKline and Eastman Chemical Company. The investment will enable Cydex to move ahead with development of several promising new pharmaceutical products. Cydex's flagship product, Captisol, enhances the delivery of drugs by improving their solubility and bioavailability.

More about Cydex: http://www.cydexinc.com